GlassScriptPhysician profile
Scott A Philburn
NPI 1386984920
$5,102.82
in general payments reported to CMS, 2019-2025
45 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $439 · 2022: $949 · 2023: $1,164 · 2024: $1,075 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.60 | 2021-2025 | |
| Novo Nordisk INC | $618.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.20 | 2021-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $323.36 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $289.25 | 2022-2025 | Rexulti |
| Pfizer INC. | $246.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $246.17 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $221.04 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $199.09 | 2021-2024 | Glassia, Trintellix |
| Glaxosmithkline, LLC. | $152.13 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Dexcom, INC. | $151.12 | 2022-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $117.76 | 2023-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $101.58 | 2021-2025 | |
| Exact Sciences Corporation | $88.06 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.63 | 2024-2025 | Caplyta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $84.98 | 2021-2025 | Injectafer |
| Seqirus USA INC | $82.10 | 2021-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Teva Pharmaceuticals USA, INC. | $76.44 | 2022 | |
| Amgen INC. | $75.96 | 2022-2025 | Prolia, Evenity, Repatha |
| Novartis Pharmaceuticals Corporation | $59.84 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $58.02 | 2022-2023 | |
| Axsome Therapeutics, INC. | $47.69 | 2025 | Symbravo, Auvelity |
| Corium, LLC | $46.74 | 2024-2025 | Azstarys |
| Alkermes, INC. | $45.61 | 2024-2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $38.74 | 2021-2022 | |
| Organon LLC | $31.08 | 2025 | Nexplanon, Nuvaring |
| Vanda Pharmaceuticals INC. | $28.48 | 2025 | Hetlioz, Fanapt |
| Radius Health, INC. | $28.00 | 2021-2024 | Tymlos |
| Medtronic, INC. | $27.97 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $27.07 | 2024 | |
| Hologic Sales and Service, LLC | $26.46 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.22 | 2021-2025 | Zoryve |
| Indivior INC. | $23.76 | 2024 | Sublocade |
| Actelion Pharmaceuticals US, INC. | $22.17 | 2025 | Opsynvi |
| Krystal Biotech INC | $21.46 | 2025 | Vyjuvek |
| Biogen, INC. | $21.11 | 2025 | Zurzuvae |
| Verona Pharma, INC. | $20.07 | 2025 | Ohtuvayre |
| Cranial Technologies, INC | $18.54 | 2025 | Doc Band |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $16.40 | 2024 | |
| Lundbeck LLC | $16.25 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $16.18 | 2023 | |
| Insmed, INC. | $16.00 | 2025 | Arikayce |
| Eisai INC. | $14.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.91 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Philburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.